MIT Technology Review发布"Impossible"期刊，对六项声称即将实现的重大技术进行进展评估1。其中，Moderna和Merck合作开发的mRNA癌症疫苗显示出显著成效，该疫苗可将黑色素瘤患者的死亡风险降低42%1。在基因编辑领域，Prime editing技术实现了首次人体临床应用，研究人员在患者的肝细胞上成功应用了这一技术1。
报道同时聚焦生物技术领域存在的监管盲点1。其中包括Palmer Luckey旗下的Warhound公司融资2亿美元用于基因增强军犬的项目1。此外，文章还涉及Starlink、PHP漏洞、Google虚拟电厂等多项科技议题1，并通过Elizabeth Holmes相关纪录片引发对科学报道透明度的思考1。
MIT Technology Review has released an evaluation of six technologies that have been touted as imminent breakthroughs, examining the current state of their development and real-world applications 1.
Among the technologies assessed is prime editing, a gene-editing technique that has now been applied to human patients for the first time, specifically targeting liver cells 1. In the cancer treatment domain, an mRNA vaccine developed jointly by Moderna and Merck has demonstrated the ability to reduce mortality risk among melanoma patients by 42 percent 1. The publication also reviewed advancements in nuclear-powered spacecraft and other emerging innovations 1.
The report, published as part of MIT Technology Review's "Impossible" journal initiative, additionally highlights regulatory blind spots within the biotechnology sector 1. This examination of biotech oversight has been informed by recent scrutiny of scientific reporting transparency, prompted by discussion surrounding a documentary about Elizabeth Holmes 1. The evaluation also touches on ventures such as Palmer Luckey's Warhound company, which secured $200 million in funding for genetic enhancement of military dogs, as well as developments in areas including Starlink, Google's virtual power plants, and PHP vulnerabilities 1.
评论
还没有评论，欢迎留下第一条。